Active ingredients: daratumumab
What it is used for
DARZALEX is indicated for the treatment of patients: with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. For use in combination with bortezomib, melphalan and prednisone. with multiple myeloma who have received at least one prior therapy. For use in combination with bortezomib and dexamethasone, or lenalidomide and dexamethasone. with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are refractory to both a PI and an immunomodulatory agent. For use as monotherapy.
How to take it
The way to take this medicine is: Intravenous. This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Protect from Light
- See Product information for shelf life
- Shelf lifetime is 24 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
DARZALEX is a colourless to yellow liquid concentrate
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient daratumumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems